June 10, 2020
Sanofi launched on June 8 its type 2 diabetes treatment Soliqua Injection SoloStar (insulin glargine + lixisenatide) in Japan. The product combines the company’s basal insulin Lantus (insulin glargine) and GLP-1 receptor agonist Lyxumia (lixisenatide) to simultaneously control fasting and...read more